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Identifying patients who are at high risk for severe 
Clostridium difﬁ  cile–associated disease (CDAD) early in 
the course of their infection may help clinicians improve 
outcomes. Therefore, we compared clinical features asso-
ciated with severe versus nonsevere CDAD by retrospec-
tively reviewing records of hospitalized patients whose fecal 
assays were positive for C. difﬁ  cile toxin. Of 336 patients, 
12.2% had severe disease and 10.1% died from all causes. 
Regression modeling showed the following to be signiﬁ  cant-
ly associated with severe CDAD (p<0.05): age >70 years 
(odds ratio [OR] 3.35), maximum leukocyte count >20,000 
cells/mL (OR 2.77), minimum albumin level <2.5 g/dL (OR 
3.44), maximum creatinine level >2 mg/dL (OR 2.47), small 
bowel obstruction or ileus (OR 3.06), and computed tomog-
raphy scan showing colorectal inﬂ  ammation  (OR  13.54). 
These clinical and laboratory markers for severe disease 
may be useful for identifying patients at risk for serious out-
comes or death.
T
he incidence and severity of Clostridium difﬁ  cile–asso-
ciated disease (CDAD) is increasing in North America 
(1–3) and Europe (4,5). During the past 10 years in the 
United States, prevalence, case-fatality rates, total attribut-
able mortality rates, and colectomy rates for persons with 
CDAD have markedly increased (6). Acquisition of C. dif-
ﬁ  cile and the development of severe CDAD is associated 
primarily with healthcare, although community-acquired 
severe disease among persons previously thought to be at 
low risk for infection have been reported (5,7,8). Several 
mechanisms for increased disease severity have been pro-
posed, including emergence of speciﬁ  c strains with genetic 
polymorphisms that encode higher levels of bacterial tox-
ins A and B and the production of a binary toxin (3,9,10). 
The Centers for Disease Control and Prevention has re-
ported outbreaks of CDAD associated with the new BI/
NAP1 strain in 40 of 50 US states, although the association 
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between BI/NAP1 and severe disease was not consistent 
among all facilities (11).
Host factors are also likely to be predictors of illness 
and death. For example, in an elderly population, leuko-
cytosis, hypoalbuminemia, and nasogastric tube feedings 
were associated with high mortality rates from CDAD (12). 
Severity of underlying illness, as measured by an increased 
Horn score, has only moderate association with severe 
CDAD (13). Exposure to speciﬁ  c antimicrobial drugs, no-
tably ﬂ  uoroquinolones, clindamycin, and cephalosporins, 
has been associated with severe CDAD in some studies 
(2,14) but not others (13). Overall, previous studies have 
identiﬁ  ed few clinical characteristics that consistently pre-
dict severe CDAD.
Identifying patients who are at high risk for severe 
CDAD early in the course of their infection might help 
clinicians improve patient outcomes, but predictors are 
not well known. Genetic subtyping, binary toxin assays, 
and culture of isolates are currently not widely accessible, 
which makes integrating knowledge of emerging bacte-
rial factors into patient management difﬁ  cult. To elucidate 
patient and clinical factors associated with severe CDAD, 
we conducted a 1-year retrospective study of Brigham and 
Women’s Hospital patients who had had positive C. dif-
ﬁ  cile toxin results.
Methods
Study Population
We performed a retrospective chart review of electron-
ic medical records for all patients who had had a positive 
fecal result for C. difﬁ  cile toxin from June 2005 through 
May 2006, a period of increased incidence of severe CDAD 
in this hospital. During June–April 2006, CDAD was diag-
nosed by cytotoxic assay for cytopathic effects in cell cul-
ture. During May 2006, our laboratory changed to a toxin 
A and B ELISA. Before assay replacement, samples were 
tested with both techniques and results were comparable 
(A. Onderdonk, pers. comm., 2008).
All inpatients >18 years of age who had had a positive 
fecal C. difﬁ  cile toxin result were included in the study. 
Ambulatory and emergency department patients were not 
included.
Study Variables and Data Collection
Study variables included those identiﬁ  ed as risk fac-
tors for development of CDAD, those associated with dis-
ease severity in previous studies, or those that logically 
predisposed patients to other severe disease outcomes. We 
collected patient demographic, historic, radiographic, and 
laboratory information.
Demographic variables included age, gender, hospital 
service (i.e., medical, surgical, obstetric, or gynecologic), 
date of positive C. difﬁ  cile toxin sample, and length of 
hospitalization. We also collected number of antimicro-
bial drug classes used during hospitalization before posi-
tive C. difﬁ  cile assay result, class and number of days used 
for each antimicrobial drug, and starting date and type of 
CDAD treatment initiated on or after the day the positive 
C. difﬁ  cile toxin samples.
Historic data included use of corticosteroids, immu-
nomodulating drugs, chemotherapy for hematologic and 
solid organ malignancies, proton pump inhibitors, and his-
tamine-2 blockers. All medication data were limited to the 
30 days before each patient’s ﬁ  rst positive C. difﬁ  cile toxin 
result. Physician-documented medical conditions included 
cardiovascular disease, diabetes mellitus, chronic kidney 
disease, past or current need for hemodialysis (not includ-
ing intensive care unit [ICU] setting), pulmonary disease, 
hematologic malignancy, solid tumor malignancy, and im-
munocompromisation (i.e., solid organ or hematopoietic 
stem cell transplantation, immunoglobulin deﬁ  ciencies, 
use of immunosuppressive agents, and severe autoimmune 
syndromes not associated with other malignancy).
Laboratory data were collected for a 7-day interval 
spanning 4 days before and 2 days after the day of submis-
sion of the ﬁ  rst C. difﬁ  cile–positive fecal specimen. This in-
terval was chosen to account for variability in the prompt-
ness of C. difﬁ  cile testing and initiation of treatment among 
healthcare providers. We recorded maximum leukocyte, 
serum glucose, creatinine, alanine aminotranferase levels, 
and minimum serum albumin concentrations.
Other variables were clinical or radiographic evi-
dence of a small bowel obstruction or ileus in addition to 
abdominal and pelvic computed tomography (CT) scans 
with abnormal ﬁ  ndings (colitis, pericolonic stranding, and 
abnormal rectal ﬁ  ndings) documented anytime during hos-
pitalization before laboratory diagnosis of CDAD. We also 
included skilled-nursing home or rehabilitation stays within 
60 days before laboratory diagnosis of C. difﬁ  cile infection, 
acute-care hospitalization within 30 days before diagnosis, 
date of death, date and number of admissions to ICU, num-
ber of surgical procedures, and enteral or total parenteral 
nutrition within 30 days before diagnosis of CDAD.
Deﬁ  nition of Severe CDAD
Patients were deﬁ  ned as having severe CDAD if they 
met at least 1 of the following criteria: 1) death within 30 
days after onset of symptoms or positive assay in which 
C. difﬁ  cile infection was a major contributor; 2) >1 ICU 
admissions in which C. difﬁ  cile infection was a major con-
tributor; 3) colectomy or other surgery directly attributed 
to C. difﬁ  cile; or 4) intestinal perforation in the presence of 
C. difﬁ  cile infection. To minimize subjectivity, cases were 
reviewed independently by 2 study personnel directly in-
volved with data collection and extraction and were count-
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ed as severe only if both reviewers agreed. A third investi-
gator, who was not involved with data collection, reviewed 
each case and acted as a tie-breaker.
Statistical Methods
The analysis was conducted in 3 stages. First, all-cause 
deaths and incidence of severe CDAD and death directly 
related to CDAD were explored in relation to age group. 
Second, univariate analyses were used to identify signiﬁ  -
cant differences in variables for patients with severe and 
nonsevere disease. Chi-square testing with continuity cor-
rection was used to compare intergroup variation between 
nonparametric variables. Fisher exact tests were used if ex-
pected counts were <5. Mann-Whitney tests of ranked data 
were used to compare ordinal/parametric variables given 
the size discrepancy between the severe– and nonsevere–
disease cohorts and to adjust for potential deviation from 
a normal distribution. Third, 2 logistic regression models 
were created. The ﬁ  rst model was designed to evaluate in-
dependent associations between disease severity and anti-
microbial drug use, demographics, and signiﬁ  cant clinical 
variables identiﬁ  ed from univariate analyses (prior nursing 
home/rehabilitation stays or acute-care hospitalizations, 
immunocompromisation, small bowel obstruction or ileus, 
and abnormal radiographic ﬁ  ndings). The second model 
was designed to assess independent associations of labo-
ratory variables with CDAD severity. Clinical variables 
likely to inﬂ  uence these laboratory values, such as hemo-
dialysis, steroid use, and chemotherapy use, were included 
in this model. We used 2 models, rather than combining all 
variables into 1 model, because the small number of severe 
CDAD cases relative to total number of CDAD cases and 
large number of variables and covariates with potential col-
linearity in a combined model would decrease the power to 
detect statistical signiﬁ  cance. Odds ratios (ORs) and 95% 
conﬁ  dence intervals were calculated for each variable in 




For the study interval, we identiﬁ  ed 336 patients and 
373 hospitalizations. However, to minimize the underesti-
mation of variance among our sample population, we ana-
lyzed data from only 1 admission per patient (initial hospi-
talization), for a total of 336 hospitalizations.
The all-cause crude mortality rate during initial admis-
sions was 10.1%. Most (82%) CDAD patients were >50 
years of age; crude mortality rate in this group was 12.0%. 
For patients <50 years of age, crude mortality rate (1.7%) 
was markedly lower; for patients >70 years of age, crude 
mortality rate was highest (15.4%) (Table 1).
The study deﬁ  nition for severe CDAD was met by 41 
(12.2%) patients. Incidence of severe CDAD among all 
patients with CDAD was markedly higher in patients >70 
years of age (p = 0.001). Of all patients, 21 (6.3%) died as 
a result of CDAD according to physician impression from 
chart review; none was <50 years of age (Table 2). Propor-
tion of severe CDAD cases among patients with CDAD 
on these services did not differ signiﬁ  cantly according to 
service (p = 0.18): 64% medical, 33% surgical, and 3% ob-
stetric or gynecologic. Numbers of days from admission 
to laboratory diagnosis of CDAD patients with or without 
severe CDAD were similar (6.6 vs. 8.2; p = 0.13), as were 
lengths of hospitalization (18.3 vs. 18.2; p = 0.70).
Univariate Analysis
Table 3 lists variables (except antimicrobial drug use) 
and laboratory values included in univariate analysis. Mean 
age of patients was 64 years. Patients with severe CDAD 
were signiﬁ  cantly older (mean age 71 years) than those 
without severe disease (mean age 63 years); p = 0.001, 
Mann-Whitney test of ranked data. Proportion of male and 
female patients with or without severe CDAD did not differ 
signiﬁ  cantly.
Other variables that did not differ signiﬁ  cantly between 
patients with or without severe CDAD were underlying 
medical illness, malignancy, use of nonantimicrobial medi-
cations (including steroids and chemotherapy), and enteral 
or parenteral feeding (Table 3). CDAD was signiﬁ  cantly 
less severe in patients who were immunocompromised or 
receiving immunosuppressive medications than in those 
who were not immunocompromised (OR 0.22, p = 0.044).
Other variables associated with severe disease includ-
ed small bowel obstruction or ileus (OR 3.33, p = 0.014), 
abdominal CT results suggestive of colorectal pathologic 
changes (OR 13.09, p<0.001), acute-care hospitalization 
within 30 days before CDAD laboratory diagnosis (OR 
2.12, p = 0.036), and rehabilitation or skilled-nursing facil-
ity stay within the 60 days before CDAD diagnosis (OR 
2.17, p = 0.043). Maximum leukocyte count was signiﬁ  -
cantly higher for patients with severe CDAD, and signiﬁ  -
cantly more patients with severe disease had a maximum 
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Table 1. All-cause deaths of inpatients with laboratory-confirmed 
CDAD, June 2005–May 2006* 
Age group, y
Total no. 
patients No. deaths % Case-fatality†
18–50 60 1 1.7
51–60 70 7 10.0
61–70 76 6 7.6
71–80 83 12 14.5
81–90 40 7 17.5
>90 7 1 14.3
Total 336 34 10.1
*CDAD, Clostridium difficile–associated disease.  
†Percentage of deaths within age group. RESEARCH
leukocyte count >20,000 cells/μL, minimum albumin level 
<2.5 g/dL, maximum glucose level >150 mg/dL, and serum 
creatinine level >2 mg/dL (Table 3).
Some exposure to antimicrobial drugs during the 30 
days before laboratory diagnosis of CDAD was noted for 
≈85% of patients. Exposure to, or number of, antimicrobial 
drugs did not differ signiﬁ  cantly among patients with or 
without severe CDAD. In the severe and nonsevere CDAD 
cohorts, 85.4% of patients had used any antimicrobial drugs 
(p = 1.0). In addition, no signiﬁ  cant differences were found 
between exposure to any of the following groups of antimi-
crobial drugs for patients with severe or nonsevere CDAD: 
ﬂ   uoroquinolones; penicillin derivatives with or without 
β-lactamase inhibitor; aminoglycosides; clindamycin; 
ﬁ   rst-generation cephalosporins; second- through fourth-
generation cephalosporins; carbapenems; trimethoprim/
sulfamethoxazole; intravenous vancomycin; systemic an-
tifungal drugs. Use of oral or intravenous metronidazole 
before laboratory diagnosis of CDAD (p = 0.860) did not 
differ signiﬁ  cantly.
Antimicrobial drugs (including oral and rectal vanco-
mycin and metronidazole) for CDAD were given to 291 
(86.7%) patients during their hospitalization. A higher per-
centage of patients with severe CDAD than without CDAD 
were treated with oral vancomycin (OR 8.27, p<0.001), 
rectal vancomycin (OR 20.35, p<0.001), or intravenous 
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Table 2. Severe CDAD and death as a result of CDAD, by age group, June 2005–May 2006* 
Age group, y Total no. patients Severe CDAD, no. (%) Deaths from CDAD, no. (%)
18–50 60 3 (5.0) 0 (0)
51–60 70 8 (11.4) 5 (7.1)
61–70 76 4 (5.2) 1 (1.3)
71–80 83 13 (15.7) 8 (9.6)
81–90 40 11 (27.5) 6 (15.0)
>90 7 2 (28.6) 1 (14.3)
Total 336 41 (12.2) 21 (6.3)
*CDAD, Clostridium difficile–associated disease.  
Table 3. Univariate analysis results for 336 patients with and without severe CDAD, June 2005–May 2006* 
Variable  All patients, %†
Severe CDAD, % 
(n = 41)‡ 
Nonsevere CDAD, % 
(n = 295)  OR§  p value 
Age >70 y  38.7  63.4  35.3  3.18  0.001¶ 
Female  48.2  51.2  47.8  1.15  0.807 
Chemotherapy use§  16.1  9.8  16.9  0.53  0.343 
Corticosteroid use§  25.6  31.7  24.7  1.41  0.444 
Proton pump inhibitor use§  63.7  61.0  64.1  0.88  0.832 
H2 blocker use  32.1  34.1  31.9  1.11  0.909 
Enteral feeding  21.7  26.8  21.0  1.38  0.520 
Parenteral feeding  3.3  2.4  3.4  0.71  1.000 
Cardiovascular disease  41.7  53.7  40.0  1.74  0.135 
Pulmonary disease  19.3  24.4  18.6  1.41  0.508 
Diabetes  22.6  22.0  22.7  0.96  1.000 
Renal disease  22.0  19.5  22.4  0.84  0.831 
Hemodialysis  6.0  4.9  6.1  0.79  1.000 
Immunocompromised  17.3  4.9  19.0  0.22  0.044¶ 
Malignancy  46.9  39.0  47.1  0.72  0.420 
Small bowel obstruction or ileus  8.3  19.5  6.8  3.33  0.014¶ 
Abnormal abdominal CT scan  28.3  78.0  21.4  13.09  <0.001¶ 
Prior hospitalization  39.9  56.1  37.6  2.12  0.036¶ 
SNF/rehabilitation stay  22.9  36.6  21.1  2.17  0.043¶ 
Max glucose level >150 mg/dL  49.1  70.7  46.1  2.83  0.005¶ 
ALT >40 U/L  23.1  28.2  22.3  1.37  0.540 
Min albumin level <2.5 g/dL  27.7  59.0  22.8  4.89  <0.001¶ 
Max creatinine level >2 mg/dL  22.0  41.5  19.3  2.96  0.003¶ 
Max leukocyte count >20,000/PL  28.3  53.7  24.7  3.52  <0.001¶ 
Mean max leukocyte count × 10
3/PL  17.6  25.8  16.5  –  <0.001¶ 
*CDAD, Clostridium difficile–associated disease; OR, odds ratio; H2, histamine-2; CT, computed tomography; SNF, skilled-nursing facility; max, 
maximum; ALT, alanine aminotransferase; min, minimum. 
†Total of 336 patients were included in analysis except for ALT (n = 286) and albumin (n = 295). 
‡n = 39 for ALT and albumin. 
§OR for severe CDAD in patients with positive C. difficile assay results; calculated for binary variables only (by Ȥ
2 or Fisher exact test) with exception of 
mean leukocyte count (significance calculated using Mann-Whitney test of ranked data). 
¶Statistically significant at Į = 0.05. Clinical Risk Factors for Severe CDAD
metronidazole (OR 4.2, p<0.001) on or after the day of lab-
oratory diagnosis of C. difﬁ  cile infection. There was no sig-
niﬁ  cant difference in frequency of severe outcomes among 
patients treated with or without oral metronidazole (OR 
1.02, p = 1.0). All patients with severe CDAD were treat-
ed with at least 1 antimicrobial drug with activity against 
C. difﬁ  cile.
Regression Analyses
The following variables from the logistic regression 
model to identify covariates independently associated with 
severe CDAD were signiﬁ  cant (p<0.05): age >70 years, 
ileus or small bowel obstruction, and abnormal abdominal 
CT image (Table 4). The following variables were not sig-
niﬁ  cantly associated with development of severe CDAD 
when adjusted for covariates: immunocompromisation sta-
tus, prior acute-care hospitalization, and stay in a skilled-
nursing facility. The independent association of laboratory 
values with severe CDAD was also investigated by using 
a single binary logistic regression model covariate adjusted 
with factors that would logically or historically inﬂ  uence 
each value. Maximum leukocyte count >20,000 cells/μL, 
maximum creatinine level >2 mg/dL, and minimum albu-
min level <2.5 g/dL were all independently associated with 
severe CDAD (p<0.05; Table 5).
Discussion
As would be expected in a general hospitalized popu-
lation, advanced age was associated with all-cause mortal-
ity rates. Similarly, the odds of severe CDAD and death 
attributable to CDAD increased with age, especially for 
patients >70 years of age. Advanced age is known to be 
associated with CDAD, but whether age inﬂ  uences the se-
verity of disease outcomes is in conﬂ  ict in different publi-
cations (3,6,12). For example, a study of 72 hospitalized 
patients with endoscopically proven pseudomembranous 
colitis showed advanced age to be associated with higher 
mortality rates, but age of patients who died of or survived 
after pseudomembranous colitis did not differ signiﬁ  cantly 
(12). In contrast, Loo et al. noted a clear increase in the 
30-day mortality rate in CDAD patients >80 years of age 
(3). In our study, no patient 18–50 years of age died as a 
result of CDAD, and advanced age was a signiﬁ  cant risk 
factor for illness and death among patients with CDAD. 
Unlike age, gender was not associated with severe CDAD; 
this ﬁ  nding is similar to those of studies that investigated 
the role of gender on development, recurrence, or sever-
ity of CDAD (12,15). However, a large US study based on 
International Classiﬁ  cation of Diseases, 9th revision, codes 
showed that CDAD case-fatality rate was higher for men 
than for women (6).
Because patients with CDAD are older and have 
more concurrent illness than the general population, effect 
of residence in long-term and acute-care facilities on the 
development and course of CDAD has generated interest 
(13,16–18). Our univariate analysis showed each of these 
variables to be associated with severe CDAD. However, 
when adjusted for age and concurrent illness, prior hospi-
talizations at long-term and acute-care facilities were not 
signiﬁ  cantly associated with severe CDAD. On the basis of 
our regression model results, it is likely that the signiﬁ  cance 
of prior hospitalizations (noted with univariate analysis) 
was the result of the more advanced age of patients who 
had had prior acute- or skilled-nursing facility hospitaliza-
tions and that age was the clinically important variable.
We found no association between malignancy or che-
motherapy and severe CDAD. In contrast, Duberkke et al. 
found that 57% of patients who had undergone allogenic 
stem cell transplant had severe CDAD, although severity of 
disease was based on grade of diarrhea and colitis (19). The 
reason for the absence of association between immunosup-
pression due to malignancy or chemotherapy and severe 
CDAD found in our study is unclear, but it is possible that 
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Table 4. Binary logistic regression model to identify variables 
independently associated with severe CDAD, 336 patients* 
Variable OR 95% CI
Age >70 y  3.35† 1.48–7.57
Female 0.93 0.42–2.03
Antimicrobial-drug use  1.76 0.60–5.21
Malignancy 0.73 0.33–1.65
Immunocompromised 0.38 0.07–1.96
Small bowel obstruction or ileus  3.06‡ 1.00–9.39
Abnormal abdominal CT scan  13.54† 5.72–32.07
Prior hospitalization  1.39 0.61–3.18
SNF/rehabilitation stay  1.11 0.46–2.68
*CDAD, Clostridium difficile–associated disease; OR, odds ratio; CI, 
confidence interval; CT, computed tomography; SNF, skilled-nursing 
facility. Constant included in analysis. 
†p<0.05. 
‡p = 0.05. 
Table 5. Binary logistic regression model to identify independent 
associations of laboratory values and pertinent variables with 
severe CDAD, 285 patients* 
Variable OR 95% CI
Age >70 y  3.24† 1.42–7.38
Female 1.16 0.51–2.62
Antimicrobial-drug use  1.04 0.35–3.12
Malignancy 0.90 0.37–2.18
Chemotherapy 1.02 0.27–3.92
Steroid use  1.13 0.48–2.68
Hemodialysis 0.5 0.8–3.01
Max leukocyte count >20,000/PL 2.77† 1.28–6.0
Max glucose level >150 mg/dL  1.46 0.63–3.43
ALT >40 U/L  1.47 0.58–3.69
Min albumin level <2.5 g/dL  3.44† 1.56–7.57
Max creatinine level  >2 mg/dL  2.47† 1.04–5.88
*CDAD, Clostridium difficile–associated disease; OR, odds ratio; CI, 
confidence interval; max, maximum; ALT, alanine aminotransferase; min, 
minimum. Constant included in analysis. 
†p<0.05. RESEARCH
at this institution, which has a large oncology and solid-
organ transplantation population, clinicians are more likely 
to order laboratory testing, implement precautions, and em-
pirically initiate treatment earlier for immunosuppressed 
patients with suspected CDAD, thus avoiding severe se-
quelae. In addition, immunosuppressive medications have 
been associated with higher mortality rates in patients with 
CDAD who do or do not have fulminant colitis, but our uni-
variate analysis results suggested that immunosuppressive 
comorbid conditions or use of immunomodulating agents 
(other than chemotherapy for malignancy) were protective 
against severe CDAD (1,15,20). However, this protective 
association was no longer noted when we adjusted for other 
factors.
Antimicrobial-drug use has been studied extensively 
with regard to development of CDAD and, to a lesser ex-
tent, severity and recurrence of disease (3,12,14,21–25). 
We found no association between severe CDAD and total 
number of antimicrobial drugs used, class of antimicrobial 
drug, and duration of exposure. In particular, use of antimi-
crobial drugs that are commonly associated with CDAD, 
including clindamycin and ﬂ  uoroquinolones, did not differ 
among patients in whom severe CDAD did and did not de-
velop. According to ﬁ  ndings of previous studies, it is prob-
able that our study population’s exposure to antimicrobial 
drugs was a risk factor for CDAD. However, antimicrobial-
drug exposure did not appear to predispose patients with 
CDAD to severe disease. Recent data also suggest that pa-
tients who continue to receive antimicrobial-drug therapy 
without activity against CDAD while being treated for 
CDAD have a higher likelihood of CDAD treatment fail-
ure (26). Our study did not take into account whether pa-
tients continued to receive antimicrobial-drug therapy after 
laboratory diagnosis of CDAD. Antimicrobial-drug stew-
ardship, however, has been shown to be useful in reducing 
CDAD rates (27).
Our univariate model showed aggressive treatment 
regimens for C. difﬁ  cile, such as intravenous metronida-
zole and oral or rectal vancomycin, to be associated with 
worse outcomes. This ﬁ  nding is likely the result of our 
standard hospital practice to upgrade treatment of the sick-
est patients from oral metronidazole to oral vancomycin, 
intravenous metronidazole, rectal vancomycin, or a com-
bination of these, so that exposure to these antimicrobial 
drugs was more likely to have been a surrogate marker of 
severe disease.
Laboratory markers such as leukocytosis, increased 
creatinine levels, and decreased albumin or globulin levels 
may correlate with poor outcome for patients with CDAD. 
Studies have yielded variable results, although multiple 
studies have shown that markedly increased leukocyte 
counts correlate with more severe disease (1,12,15,20). 
Similarly, our logistic regression model showed the fol-
lowing variables to be signiﬁ  cantly correlated with severe 
CDAD: maximum leukocyte count >20,000/μL, minimum 
serum albumin level <2.5 g/dL, and maximum serum crea-
tinine level >2 mg/dL. These laboratory values were ad-
justed for potential effects of concurrent underlying clinical 
conditions or treatments, such as hemodialysis, and use of 
steroids or chemotherapy. We also found some radiograph-
ic abnormalities to be associated with severe disease. On 
the basis of the results of our analyses, laboratory and im-
aging abnormalities may be useful for predictive modeling 
of severe outcomes from CDAD.
One major limitation of this study was our dependence 
on the date of laboratory diagnosis of CDAD to deﬁ  ne dis-
ease onset. Clinical signs and symptoms (e.g., diarrhea, 
bloody feces, or abdominal pain) may have developed 
before the patient was tested for CDAD, and the date of 
laboratory diagnosis likely reﬂ  ected the timing of physi-
cians’ clinical suspicion for C. difﬁ  cile infection rather than 
exact onset of symptoms. Our inability to reliably assess 
the presence of diarrhea may also have resulted in inclu-
sion of some patients colonized with but not clinically ill 
from C. difﬁ  cile. In addition, we found that several patients 
had been treated with oral vancomycin before laboratory 
diagnosis of CDAD and that severe disease was more likely 
to develop in patients treated before laboratory diagnosis. 
These patients were likely treated on grounds of clinical 
suspicion and may have had more aggressive onset and 
worse clinical markers for disease before laboratory diag-
nosis. We also did not evaluate whether cessation or con-
tinuation of antimicrobial drugs other than metronidazole 
and oral vancomycin affected progression to severe C. dif-
ﬁ  cile infection.
As discussed previously, maximum and minimum lab-
oratory values were collected for the time interval spanning 
the 4 days before and 2 days after the day of submission of 
the ﬁ  rst C. difﬁ  cile–positive specimen. We included the 2 
days after laboratory diagnosis to account for variability in 
the timing of recognition and response to positive C. dif-
ﬁ  cile assay results, but this fairly broad time interval limits 
to some extent our ability to evaluate the diagnostic utility 
of these laboratory values. Abnormal creatinine levels and 
leukocyte counts during this 7-day interval, for example, 
may have reﬂ  ected the natural history and course of severe 
disease and skewed values higher for patients with severe 
CDAD. Finally, growing evidence indicates that BI-NAP 
0127 causes more severe CDAD, and in our population 
bacterial subtype was likely an unrepresented predictor of 
severe disease.
The results of our study suggest that readily available 
clinical data, such as age and basic laboratory and radiol-
ogy data, are correlated with severe CDAD outcomes. 
These ﬁ  ndings suggest that clinicians may be able to gauge 
the risk for severe outcomes without individual genotyp-
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ing. This ability is likely to be valuable in community as 
well as tertiary-care settings. Use of these markers for early 
identiﬁ  cation of patients at high risk for severe disease may 
facilitate rapid implementation of aggressive medical and 
surgical CDAD therapy.
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